Home · Health · Sep 23 archive
FDA Panel Endorses Grail's Galleri Blood Test for Cancer
Developing
In Short: An FDA advisory panel voted to endorse Grail's Galleri blood test, which screens for multiple types of cancer, saying its benefits outweigh risks.
An FDA advisory panel on Wednesday voted to endorse Grail's Galleri blood test, which screens for multiple types of cancer, concluding that the benefits of the test outweigh its risks.
The panel voted 10 to 0 that the test is safe and 6 to 4 that it is effective. They also voted 7 to 2 with one abstention that the benefits of Galleri outweigh the risks for patients who meet the specified criteria.
The FDA is not required to follow the advice of these panels, but it often does.
Grail's Galleri test is designed to detect over 50 types of cancer through a single blood draw, potentially allowing for early detection and treatment.
The panel's endorsement is a significant step toward the potential approval and widespread use of the Galleri test, which could revolutionize cancer screening methods.
What's still developing
- To read the rest of this story subscribe to STAT+.
- You may opt out of receiving STAT communications at any time.